Breaking News Instant updates and real-time market news.

TWTR

Twitter

$19.87

-5 (-20.10%)

, BAC

Bank of America

$16.22

0.11 (0.68%)

08:55
10/07/16
10/07
08:55
10/07/16
08:55

Notable open interest changes for October 7th

Thursday's total option volume of 13.9 million contracts resulted in net open interest growth of 2.32 million calls and 1.97 million puts. Twitter (TWTR), Bank of America (BAC), Valeant Pharmaceuticals (VRX) and General Motors (GM) saw the greatest growth. Top five new positions opened include 57k General Motors (GM) Mar-17 37 calls, 39k Bank of America (BAC) 10/7 weekly 16 puts, 26k Valeant Pharmaceuticals (VRX) Jan-17 27.5 calls, 26k Valeant Pharmaceuticals (VRX) Jan-17 42.5 calls and 23k Bank of America (BAC) 10/7 weekly 16.5 calls.

TWTR

Twitter

$19.87

-5 (-20.10%)

BAC

Bank of America

$16.22

0.11 (0.68%)

VRX

Valeant

$23.68

-0.91 (-3.70%)

GM

General Motors

$32.53

-0.15 (-0.46%)

  • 23

    Oct

  • 25

    Oct

  • 16

    Nov

  • 30

    Nov

TWTR Twitter
$19.87

-5 (-20.10%)

10/07/16
ADAM
10/07/16
NO CHANGE
Target $95
ADAM
Buy
Salesforce worthy of investor consideration at current levels, says Canaccord
Canaccord analyst Richard Davis came away from the Salesforce (CRM) Dreamforce week more enthused about the company's outlook. The analyst noted the company is growing its revenues 3.5 times faster than it legacy peers. Davis noted the company's CEO said they are very disciplined on price when it comes to acquisitions and believes that they would not be interested in Twitter (TWTR) at its rumored asking price of $28 per share. Davis reiterated his Buy rating and $95 price target on Salesforce shares.
10/07/16
PIPR
10/07/16
NO CHANGE
Target $100
PIPR
Overweight
Piper sees 'clouds parting' on Salesforce valuation
Salesforce CEO Marc Benioff mostly calmed nerves over a potential Twitter (TWTR) acquisition by saying at the company's analyst day, "While we look at everything, we pass on almost everything," Piper Jaffray analyst Alex Zukin tells investors in a research note. The comment does not completely take a deal for Twitter off the table, but the probability of a transformational acquisition is now "dramatically lower," Zukin contends. As such, the analyst feels the "clouds are parting" on Salesforce's valuation "with sunshine ahead." Zukin believes the company has a "clear line of sight" to $10B in revenue in FY17. He keeps an Overweight rating on the shares with a $100 price target. Salesforce closed yesterday up $2.84, or 4%, to $71.26.
10/06/16
BMOC
10/06/16
NO CHANGE
BMOC
Twitter acquisition would hurt Salesforce, says BMO Capital
BMO Capital analyst Keith Bachman says that an acquisition of Twitter (TWTR) by Salesforce (CRM) would " offer little strategic fit, would slow revenue growth and would be dilutive to (free cash flow) margins." Bachman thinks that the deal would cause Salesforce's stock to drop significantly,. and he says that the company's stock would be worth $65 if it pulls the trigger on Twitter. The analyst says that Salesforce's current valuation is attractive if it does not buy Twitter. He keeps an $86 price target and Outperform rating on Salesforce.
10/06/16
COWN
10/06/16
NO CHANGE
Target $100
COWN
Outperform
Salesforce shares should rebound with no Twitter deal, says Cowen
Cowen analyst J.Derrick Wood expects shares of Salesforce (CRM) to rebound if the company does not buy Twitter (TWTR), which he believes will not happen. The analyst believes investors will return to fundamentals and the analyst believes upside momentum in Salesforce's core business will return in Q3. Wood reiterated his Outperform rating and $100 price target on Salesforce shares.
BAC Bank of America
$16.22

0.11 (0.68%)

09/16/16
GSCO
09/16/16
NO CHANGE
Target $19
GSCO
Conviction Sell
Bank of America operating leverage hitting an inflection, says Goldman
Goldman analyst Richard Ramsden believes Bank of America is hitting an inflection point in operating leverage driven by low single digit growth, stable credit, and absolute reductions in the expense base. The analyst believes topline growth will reach approximately 4% annually through to 2018, driven by consumer bank and wealth management initiatives. Ramsden reiterates his Conviction Buy rating on Bank of American and raised his price target to $19 from $17 given the combination of revenue growth and expense discipline.
09/13/16
SOCG
09/13/16
DOWNGRADE
Target $42
SOCG
Sell
Societe Generale cuts Citi to Sell, Bank of America to Hold
Societe Generale downgraded Citi (C) to Sell from Hold and Bank of America (BAC) to Hold from Buy. The firm has a $42 price target for shares of Citi and attributes an increased negative stance on Cards for the downgrade. Societe Generale has a $17 price target for Bank of America and cites revenue growth for the downgrade to Hold. Citi is trading down 86c to $46.93 and Bank of America is trading down 19c to $15.71.
09/13/16
SOCG
09/13/16
DOWNGRADE
SOCG
Hold
Bank of America downgraded to Hold from Buy at Societe Generale
08/25/16
GSCO
08/25/16
NO CHANGE
Target $17
GSCO
Buy
Bank of America at an inflection point, says Goldman
Goldman analyst Richard Ramsden believes Bank of America's operating leverage is at an inflection point as revenue growth and cost reductions from back office rationalization take effect. Ramsden met with CEO Moynihan and said he believes the company can grow core loans, without compromising credit quality, at mid-single digit rates, and expects the fee-based businesses to benefit from growth in checking accounts, mortgage activity, and market share gains. Ramsden believes Bank of America can achieve 10% ROTCE and views valuation as compelling. He rates shares a Buy with a $17 price target.
VRX Valeant
$23.68

-0.91 (-3.70%)

09/19/16
WELS
09/19/16
NO CHANGE
WELS
Price increases could be negative sign, says Wells Fargo
After Valeant increased the list prices of three of its products with combined sales of $1.2M last year, Wells Fargo says further price increases could be forthcoming, and the price increases could indicate that the company feels it needs to raise prices to meet its 2H16 guidance. Noting that the company raised the list price on each of the products by 9.9%, Wells believes that the company could have raised prices by that amount instead of 10% to "stay under the radar of managed care plans and states" looking to prevent double digit price increases. Wells keeps an Underperform rating on the stock.
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Underperform
Valeant legal woes may present bigger risk than realized, says Wells Fargo
Wells Fargo analyst David Maris said in a new note to investors that he continues to think investors are underestimating the potential downside posed by Valeant's legal troubles, whose stakes "might not be in the tens of millions, but much larger." Maris, who has kept an Underperform rating on Valeant Pharmaceuticals (VRX) since starting coverage of the stock in February, notes that the company has not taken any reserves for Allergan (AGN) or Philidor-related litigation.
09/20/16
DBAB
09/20/16
INITIATION
Target $30
DBAB
Hold
Valeant reinstated with a Hold at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert reinstated coverage of Valeant Pharmaceuticals with a Hold rating and $30 price target. Potential fines from the numerous investigations into the company are difficult to predict, Gilbert tells investors in a research note. The analyst assumes revenue for Valeant's dermatology business will begin to rebound in the second half of 2016 and into 2017. Before restricting coverage on the name, Deutsche had a Hold rating on the shares.
09/23/16
WELS
09/23/16
NO CHANGE
WELS
Underperform
Wells thinks Valeant's $1B acquisition in 2015 could be worth $50M or less
Wells Fargo analyst David Maris believes Valeant Pharmaceuticals will take a large impairment charge on the carrying value of Sprout, perhaps as much as 90% of its value. Sprout won approval in 2015 for Addyi, the first pill to aid a woman's sex drive. Valeant bought Sprout for $1B in August 2015, and in December 2015 forecasted sales of $100M-$150M, Maris points out. With sales in July, according to IMS, reaching only $696,235, Maris thinks Addyi "has no chance" of reaching $100M in 2016 and "might not even reach" $10M. He believes Sprout may be worth $50M or less. Without an add-back to adjusted earnings going forward, the [potential write-off would have a 14c per share impact to annual adjusted earnings in 2017 and beyond, Maris tells investors in a research note. Further, he believes Valeant could have other assets with this same problem, compounding the company's divestiture plans. Maris keeps an Underperform rating on Valeant with a $17-$22 price target range. The drugmaker closed yesterday down 12c to $26.85.
GM General Motors
$32.53

-0.15 (-0.46%)

10/06/16
GSCO
10/06/16
NO CHANGE
GSCO
Autos and Autos Parts sector downgraded to Cautious from Neutral at Goldman
Goldman analyst David Tamberrino downgraded the Autos and Auto Parts sector to Cautious from Neutral saying the US Auto cycle peaked in 2015 and is being held up by increasing OEM incentives. The analyst said OEM earnings will decline in 2017/2018 as negative pricing and lower production pressure North American results, but expects suppliers' earnings to hold up longer. The analyst sees upside to Delphi (DLPH) and Harman (HAR) given exposure to secular growth areas and upside to Goodyear Tire (GT) given secular HVA tire growth. Tamberrino downgraded Lear (LEA) to Sell citing elevated expectations and valuation, cut BorgWarner (BWA) to Neutral on valuation, downgraded Tesla (TSLA) to Neutral on execution risk and capital deployment, and upgraded AutoNation (AN) to Neutral given a more defensive business.
09/20/16
NOMU
09/20/16
INITIATION
Target $33
NOMU
Neutral
General Motors initiated with a Neutral at Nomura
Nomura analyst Anindya Das initiated General Motors with a Neutral and a $33 price target. The analyst said General Motors has significant exposure to the Chinese auto market and is concerned about pricing pressures in the market. Further, the company has yet to break even in Europe on an annual basis and its near-term prospects are clouded by Brexit uncertainties.
09/19/16
09/19/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he believes even flat earnings in 2017 and 2018 would be received as a positive surprise by the market. 2. Wells Fargo (WFC) upgraded to Outperform from Neutral at Baird analyst David George saying he believes the recent pullback is a buying opportunity. 3. Lockheed Martin (LMT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Sam Pearlstein saying he believes the company's earnings can grow 20% per year through 2020. 4. U.S. Steel (X), AK Steel (AKS), and Olympic Steel (ZEUS) were upgraded to Sector Weight from Underweight at KeyBanc with analyst Ivan Marcuse saying the stocks at current levels better reflect the more competitive market conditions he expects in Q4 and 2017. 5. Mattel (MAT) upgraded to Buy from Neutral at Monness Crespi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/16
09/19/16
UPGRADE
Target $37

Overweight
General Motors upgraded to Overweight at Morgan Stanley
As previously reported, Morgan Stanley upgraded General Motors to Overweight from Equal Weight and increased its price target to $37 from $29. Analyst Adam Jonas raised near-term earnings estimates 5% above consensus and believes even flat earnings in 2017 and 2018 would be received as a positive surprise by the market. Further, the analyst said investors are underestimating how long the auto cycle can last and that General Motor's earnings and free cash flow could have a materially longer duration than the market is currently discounting. He believes investors are overlooking the time and steps needed for fully autonomous transport and said management has a healthy and realistic acceptance that it can't and should not do everything alone and will likely explore new business structures with the potential of positive values.

TODAY'S FREE FLY STORIES

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.